112859-71-9
Chemical Structure
Fluasterone
- CAS No.: 112859-71-9
- Formula:C19H27FO
- Molecular Weight:290.42
IUPAC Name: (8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-17H-cyclopenta[a]phenanthren-17-one
InChIKey: VHZXNQKVFDBFIK-NBBHSKLNSA-N
SMILES: C[C@@]12[C@](C[C@@H](F)C2=O)([H])[C@@]3([H])[C@]([C@@]4(C(CCCC4)=CC3)C)([H])CC1
Biological Activity: Fluasterone is a potent G6PD inhibitor with a Ki of 0.51 μM. Fluasterone has anti-inflammatory, cancer preventive, and anti-diabetic effects. Fluasterone is orally active[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fluasterone | 99.84% | Fluasterone is a potent G6PD inhibitor with a Ki of 0.51 μM. Fluasterone has anti-inflammatory, cancer preventive, and anti-diabetic effects. Fluasterone is orally active. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fluasterone (Standard) | ≥98% | Fluasterone (Standard) is the analytical standard of Fluasterone. This product is intended for research and analytical applications. Fluasterone is a potent G6PD inhibitor with a Ki of 0.51 μM. Fluasterone has anti-inflammatory, cancer preventive, and anti-diabetic effects. Fluasterone is orally active. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Schwartz AG, et al. Suppression of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal hyperplasia and inflammation by the dehydroepiandrosterone analog 16alpha-fluoro-5-androsten-17-one and its reversal by NADPH liposomes. Cancer Lett. 2001 Jul 10;168(1):7-14. [Content Brief]
- [2]. Schwartz AG, et al. Potential therapeutic use of dehydroepiandrosterone and structural analogs. Diabetes Technol Ther. 2001 Summer;3(2):221-4. [Content Brief]
- [3]. Pashko LL, et al. Antihyperglycemic effect of dehydroepiandrosterone analogue 16 alpha-fluoro-5-androsten-17-one in diabetic mice. Diabetes. 1993 Aug;42(8):1105-8. [Content Brief]
Keywords